+44 20 8123 2220
info@marketpublishers.com

Global DNA Damage Response Drugs Market: Focus on Commercialized Drugs, Potential Pipeline Drugs, Application, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

https://marketpublishers.com/r/G7A9338B0108EN.html
Date: August 2020
Pages: 247
Price: US$ 5,000.00 (Single User License)
ID: G7A9338B0108EN

Abstracts

Hard copy option is available on any of the options above at an additional charge of $500. Please email us at order@marketpublishers.com with your request.

Market Report Coverage - DNA Damage Response Drugs

Market Segmentation

Commercialized Drugs – Lynparza, Talzenna, Zejula, and Rubraca

Pipeline Analysis (by Mechanism of Action)- PARP Inhibitor, WEE1 Kinase Inhibitor, ATR Kinase Inhibitor, Aurora B Inhibitor, and DNA-PK Inhibitor, and Others

Application – Ovarian Cancer, Breast Cancer, Pancreatic Cancer, and Prostate Cancer

Regional Segmentation

North America – U.S., Canada

Europe – Germany, France, U.K., Italy, Spain, Switzerland, and Rest-of-Europe

+44 20 8123 2220
info@marketpublishers.com

Asia-Pacific – China, Japan, India, Australia, and Rest-of-Asia-Pacific (RoAPAC)

Latin America – Brazil, and Rest-of-the-Latin America

Rest-of-the-World

Growth Drivers

Rising Global Prevalence of Cancer

Favourable Regulatory Environment

Increasing Oncology R&D Expenditure

Increase in Adoption of Precision Medicine in Cancer Treatment

Market Challenges

High Cost Hindering the Adoption Rate

Unfavorable Reimbursement Scenario

Safety Concerns Pertaining to Severe Adverse Effects

Market Opportunities

Massive Scope in Emerging Regions

Key Companies Profiled

AbbVie Inc., AstraZeneca plc, Bayer AG, BeiGene Ltd., Clovis Oncology, Debiopharm International SA, Eli Lilly & Company, GlaxoSmithKline plc, Merck KGaA, NMS Group S.p.A, Onxeo SA, Pfizer Inc., Repare Therapeutics, Sierra Oncology, Inc., and Zentalis Pharmaceuticals, LLC

+44 20 8123 2220
info@marketpublishers.com

Key Questions Answered in this Report:

What are the major market drivers, challenges, and opportunities in the global DNA damage response drugs market?

What are the underlying structures resulting in the emerging trends within the global DNA damage response drugs market?

What are the key development strategies that are being implemented by the major players in order to sustain in the competitive market?

What are the key regulatory implications in developed and developing regions for the DNA damage response drugs?

What is the pricing and reimbursement scenario for DNA damage response drugs market?

What is the implication of the COVID-19 pandemic on the oncology research?

What are the potential DNA damage response drugs present in the pipeline?

What is the clinical landscape of DNA damage response drugs market?

How is each segment of the market expected to grow during the forecast period from 2020 to 2030? What is the anticipated revenue to be generated by each of the segments on the basis of:

Commercialized Drugs (Lynparza, Talzenna, Zujula, and Rubraca)

Potential Pipeline Drugs (PARP Inhibitor, WEE1 Kinase Inhibitor, ATR Kinase Inhibitor, Aurora B Inhibitor, DNA-PK Inhibitor, and Others)

Application (Ovarian Cancer, Breast Cancer, Pancreatic Cancer, and Prostate Cancer)

Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)

+44 20 8123 2220
info@marketpublishers.com

Who are the leading players with significant offerings to the global DNA damage response drugs market? What is the expected market dominance for each of these leading players?

Which companies are anticipated to be highly disruptive in the future, and why?

What are the current treatment gaps, and how are DNA damage response drugs anticipated to fill these gaps?

How does cancer burden impact the development of DNA damage response drugs worldwide?

What are the unmet needs that are currently being faced?

Market Overview

Our healthcare experts have found DNA damage response drugs industry to be one of the most rapidly evolving markets. The global market for DNA damage response drugs is predicted to grow at a CAGR of 21.33% over the forecast period of 2020-2030. The market is driven by certain factors, which include the rising global prevalence of cancer, favorable reimbursement scenario, increasing oncology R&D expenditure, and an increase in the adoption of precision medicine in cancer treatment.

The market is favored by the developments in the field of oncology research for discovering underlying molecular mechanisms of cancerous cells for the development of novel therapeutics. Moreover, the growing cases of advanced cancer worldwide has significantly escalated the need for developing DNA damage response drugs for solving cancer unmet needs. These drugs have unprecedented potential in terms of offering a selective and efficient tolerated treatment approach for improving cancer survival rates.

Within the research report, the market is segmented on the basis of commercialized drugs, pipeline analysis (by mechanism of action), application, and region. The commercialized drugs segment contains the revenue which is expected to be generated by the successful launch of commercialized drugs that are in Phase III clinical trials and are being evaluated for other cancer indications based on different biomarkers. The pipeline analysis (by mechanism of action) segment covers non-commercialized DNA damage response drugs that are currently in Phase III clinical trials and are being developed as a monotherapy treatment for various cancer indications. Each of these

+44 20 8123 2220
info@marketpublishers.com

segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.

Competitive Landscape

The exponential rise in the application of precision medicine on the global level has created a buzz among the pharmaceutical companies to invest in the development of small molecule cancer drugs. Due to the diverse product and pipeline portfolio and intense market penetration, AstraZeneca plc has been a pioneer in this field and has been a significant competitor in this market.

Several other companies such as GlaxoSmithKline plc, Pfizer Inc., and Clovis Oncology, have also launched their respective DNA damage response drugs, such as Zejula, Talzenna, and Rubraca, respectively, to compete with Lynparza’s market dominance.

On the basis of region, North America holds the largest share of DNA damage response drugs market due to the availability of capital and cancer research expertise, growing need to develop novel cancer therapeutics, and high adoption of precision medicine, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period.

+44 20 8123 2220
info@marketpublishers.com

Contents

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

+44 20 8123 2220
info@marketpublishers.com

List Of Tables

LIST OF TABLES

+44 20 8123 2220
info@marketpublishers.com

Table 12.8: DNA Damage Response (DDR) Drugs for Prostate Cancer: Pipeline Products

+44 20 8123 2220
info@marketpublishers.com

I would like to order

Product name: Global DNA Damage Response Drugs Market: Focus on Commercialized Drugs, Potential Pipeline Drugs, Application, Country Data (13 Countries), and Competitive Landscape - Analysis and Forecast, 2020-2030

Product link: https://marketpublishers.com/r/G7A9338B0108EN.html

Price: US$ 5,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/G7A9338B0108EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

**All fields are required

Custumer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below

+44 20 8123 2220
info@marketpublishers.com

and fax the completed form to +44 20 7900 3970